Related Experiment Video
Updated: Jul 14, 2026
10:35
Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
Published on: February 5, 2021
The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant
Thomas Ebensen1, Kai Schulze, Peggy Riese
1Department of Vaccinology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig, Germany.
Clinical and Vaccine Immunology : CVI
|June 15, 2007
Summary
Bis(3',5')-cyclic dimeric GMP (cdiGMP) acts as a potent mucosal adjuvant, enhancing immune responses to intranasal vaccines. This cyclic dinucleotide stimulates significant antibody and cellular immunity, showing promise for new vaccine development.
Area of Science:
- Immunology
- Vaccinology
- Microbiology
Background:
- Mucosal adjuvants are crucial for effective vaccine delivery.
- Bis(3",5")-cyclic dimeric GMP (cdiGMP), a microbial second messenger, modulates cell surface properties.
Purpose of the Study:
- To investigate the adjuvant activity of cdiGMP for mucosal vaccines.
- To evaluate the impact of cdiGMP on humoral and cellular immune responses.
Main Methods:
- BALB/c mice were intranasally immunized with beta-galactosidase (beta-Gal) and cdiGMP.
- Humoral responses (IgG, IgA) and cellular responses (Th1, CTL) were assessed.
- C57BL/6 mice were immunized with ovalbumin and cdiGMP to evaluate cytotoxic T-lymphocyte responses.
Main Results:
- cdiGMP significantly increased anti-beta-Gal IgG titers (512-fold) and stimulated secretory IgA in mucosal tissues.
- cdiGMP promoted a dominant Th1 immune response pattern.
- In vivo cytotoxic T-lymphocyte responses were stimulated in mice immunized with ovalbumin and cdiGMP.
Conclusions:
- cdiGMP demonstrates potent mucosal adjuvant activity.
- cdiGMP enhances both humoral and cellular immunity, including Th1 and cytotoxic T-lymphocyte responses.
- cdiGMP is a promising candidate for the development of novel mucosal vaccines.
